Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993015priorityCriticalpatent/ECSP993015A/en
Publication of ECSP993015ApublicationCriticalpatent/ECSP993015A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Composiciones que comprenden partículas de base libre de ziprasidona cristalina o de hidrocloruro de ziprasidona cristalino, que tienen un tamaño medio de particulas inferior a 85 um y un vehículo farmacéuticamente aceptable son sustancialmente bioequivalente y se pueden usar para tratar psicósis, como esquizofrenia.Compositions comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles, having an average particle size of less than 85 um and a pharmaceutically acceptable carrier are substantially bioequivalent and can be used to treat psychoses, such as schizophrenia.